Milnacipran for the Treatment of Fibromyalgia

Overview

Journal Health Psychol Res

Date 2021 Nov 8

PMID 34746490

Citations 6

Authors

Harshit Gupta

Brook Girma

Jack S Jenkins

Sarah E Kaufman

Christopher A Lee

Alan D Kaye

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This is a comprehensive review of the literature regarding the use of milnacipran in treating fibromyalgia. A chronic pain disorder with other system disturbances, fibromyalgia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for using milnacipran as a treatment option for this condition.

Recent Findings: The definition of fibromyalgia has evolved over many years as it is a relatively tricky syndrome to measure objectively. Today, it is characterized by chronic, widespread pain accompanied by alterations in sleep, mood, and other behavioral aspects. A variety of therapeutic regimens currently used to treat the syndrome as a singular approach are rarely effective.Milnacipran is one of three drugs currently approved by the FDA for the treatment of fibromyalgia. It acts as a serotonin and norepinephrine reuptake inhibitor, which results in decreased pain transmission. Milnacipran remains an effective treatment option for fibromyalgia in adults and needs to be further evaluated with existing therapeutic approaches.

Summary: Fibromyalgia is a broad-spectrum disorder primarily characterized by chronic pain coupled with disturbances in cognitive functioning and sleep. The progression of this syndrome is often debilitating and significantly affects the quality of life. Milnacipran is one of three FDA-approved drugs used to alleviate the symptom burden and is comparatively more therapeutic in specific domains of fibromyalgia. A more holistic approach is needed to treat fibromyalgia effectively and further research, including direct comparison studies, should be conducted to fully evaluate the usefulness of this drug.

Citing Articles

Fibromyalgia and Inflammation: Unrevealing the Connection.

Garcia-Dominguez M Cells. 2025; 14(4).

PMID: 39996743 PMC: 11853252. DOI: 10.3390/cells14040271.

A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.

Garcia-Dominguez M Biomedicines. 2025; 13(1).

PMID: 39857749 PMC: 11762748. DOI: 10.3390/biomedicines13010165.

Fibromyalgia: do I tackle you with pharmacological treatments?.

Perrot S Pain Rep. 2025; 10(1):e1222.

PMID: 39801722 PMC: 11723698. DOI: 10.1097/PR9.0000000000001222.

Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.

Faizan Ejaz K, Wani R, Akbar A, Umaira Khan Q, Ishtiaq H, Amir M Cureus. 2025; 16(12):e76631.

PMID: 39744264 PMC: 11693412. DOI: 10.7759/cureus.76631.

Understanding Non-Pharmacological Treatments for Fibromyalgia Functional and Well-Being Status: The Role of Literacy.

Amzolini A, Neagoe C, Avramescu T, Mitrea A, Traistaru R, Micu E Healthcare (Basel). 2024; 12(19).

PMID: 39408136 PMC: 11475347. DOI: 10.3390/healthcare12191956.

References

Sommer C, Hauser W, Alten R, Petzke F, Spath M, Tolle T . [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. Schmerz. 2012; 26(3):297-310. DOI: 10.1007/s00482-012-1172-2. View

Maj J, Rogoz Z, Dlaboga D, Dziedzicka-Wasylewska M . Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems. J Neural Transm (Vienna). 2001; 107(11):1345-59. DOI: 10.1007/s007020070022. View

Queiroz L . Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep. 2013; 17(8):356. DOI: 10.1007/s11916-013-0356-5. View

Chinn S, Caldwell W, Gritsenko K . Fibromyalgia Pathogenesis and Treatment Options Update. Curr Pain Headache Rep. 2016; 20(4):25. DOI: 10.1007/s11916-016-0556-x. View

Tzadok R, Ablin J . Current and Emerging Pharmacotherapy for Fibromyalgia. Pain Res Manag. 2020; 2020:6541798. PMC: 7036118. DOI: 10.1155/2020/6541798. View

Borchers A, Gershwin M . Fibromyalgia: A Critical and Comprehensive Review. Clin Rev Allergy Immunol. 2015; 49(2):100-51. DOI: 10.1007/s12016-015-8509-4. View

Arnold L, Palmer R, Ma Y . A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain. 2013; 29(12):1021-8. DOI: 10.1097/AJP.0b013e31828440ab. View

Hauser W, Bernardy K, Uceyler N, Sommer C . Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain. 2009; 145(1-2):69-81. DOI: 10.1016/j.pain.2009.05.014. View

Younger J, Noor N, McCue R, Mackey S . Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013; 65(2):529-38. DOI: 10.1002/art.37734. View

10.

Baron E . Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Headache. 2015; 55(6):885-916. DOI: 10.1111/head.12570. View

11.

Periclou A, Palmer R, Zheng H, Lindamood 3rd C . Effects of milnacipran on cardiac repolarization in healthy participants. J Clin Pharmacol. 2010; 50(4):422-33. DOI: 10.1177/0091270009346059. View

12.

Mochizuki D, Hokonohara T, Kawasaki K, Miki N . Repeated administration of milnacipran induces rapid desensitization of somatodendritic 5-HT1A autoreceptors but not postsynaptic 5-HT1A receptors. J Psychopharmacol. 2002; 16(3):253-60. DOI: 10.1177/026988110201600311. View

13.

Distler O, Eich W, Dokoupilova E, Dvorak Z, Fleck M, Gaubitz M . Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2009; 62(1):291-300. DOI: 10.1002/art.25062. View

14.

Pae C, Marks D, Shah M, Han C, Ham B, Patkar A . Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009; 32(6):355-63. DOI: 10.1097/WNF.0b013e3181ac155b. View

15.

Trugman J, Palmer R, Ma Y . Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study. Curr Med Res Opin. 2013; 30(4):589-97. DOI: 10.1185/03007995.2013.861812. View

16.

Imbierowicz K, Egle U . Childhood adversities in patients with fibromyalgia and somatoform pain disorder. Eur J Pain. 2003; 7(2):113-9. DOI: 10.1016/S1090-3801(02)00072-1. View

17.

Behlke L, Lenze E, Carney R . The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs. 2020; 34(11):1133-1147. PMC: 7666056. DOI: 10.1007/s40263-020-00763-z. View

18.

Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B . Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013; (1):CD010292. DOI: 10.1002/14651858.CD010292. View

19.

Clauw D . Fibromyalgia: a clinical review. JAMA. 2014; 311(15):1547-55. DOI: 10.1001/jama.2014.3266. View

20.

Verbunt J, Pernot D, Smeets R . Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008; 6:8. PMC: 2265693. DOI: 10.1186/1477-7525-6-8. View